» Authors » Ira M Jacobson

Ira M Jacobson

Explore the profile of Ira M Jacobson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 175
Citations 10440
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Block T, Guo J, Zoulim F, Rice C, Thio C, Schneider W, et al.
Nat Rev Gastroenterol Hepatol . 2025 Feb; 22(3):150-151. PMID: 39910374
No abstract available.
2.
Tu T, McQuaid T, Jacobson I
Liver Int . 2024 Dec; 45(1):e16202. PMID: 39720865
Background: Chronic hepatitis B virus (HBV) infection is a common but underdiagnosed and undertreated health condition and is the leading cause of hepatocellular carcinoma (HCC) worldwide. HBV (rated a Grade...
3.
de Jong Y, Jacobson I
J Viral Hepat . 2024 Apr; 31 Suppl 1:35-40. PMID: 38606953
Hepatocellular carcinoma (HCC) has long been recognized as a complication in people with chronic liver disease, particularly those with cirrhosis. Two gene therapies for haemophilia A and B recently approved...
4.
Yuen M, Fung S, Ma X, Nguyen T, Hassanein T, Hann H, et al.
JHEP Rep . 2024 Mar; 6(4):100999. PMID: 38510983
Background & Aims: The investigational first-generation core inhibitor vebicorvir (VBR) demonstrated safety and antiviral activity over 24 weeks in two phase IIa studies in patients with chronic HBV infection. In...
5.
Jacobson I
Gastroenterol Hepatol (N Y) . 2024 Feb; 20(2):123-126. PMID: 38414910
No abstract available.
6.
Gish R, Jacobson I, Lim J, Waters-Banker C, Kaushik A, Kim C, et al.
Hepatology . 2023 Nov; 79(5):1117-1128. PMID: 37976395
Background And Aims: HDV leads to the most severe form of viral hepatitis; however, the prevalence of HDV is not well understood. Using real-world data from the All-Payer Claims Database,...
7.
Su F, Jacobson I
Clin Liver Dis . 2023 Oct; 27(4):791-808. PMID: 37778770
The main aim of antiviral therapy in patients with chronic hepatitis B (CHB) is to prevent disease progression and reduce the risk of hepatocellular carcinoma (HCC). In general, treatment is...
8.
Pan C, Gish R, Jacobson I, Hu K, Wedemeyer H, Martin P
Dig Dis Sci . 2023 Aug; 68(10):4062-4063. PMID: 37558801
No abstract available.
9.
Yuen M, Asselah T, Jacobson I, Brunetto M, Janssen H, Takehara T, et al.
Lancet Gastroenterol Hepatol . 2023 Jul; 8(9):790-802. PMID: 37442152
Background: JNJ-73763989 (JNJ-3989), a small interfering RNA, targets all hepatitis B virus (HBV) RNAs, reducing all HBV proteins. JNJ-56136379 (JNJ-6379; also known as bersacapavir), a capsid assembly modulator, inhibits HBV...
10.
Pan C, Gish R, Jacobson I, Hu K, Wedemeyer H, Martin P
Dig Dis Sci . 2023 Jun; 68(8):3237-3248. PMID: 37338616
Hepatitis D virus (HDV) depends on hepatitis B virus (HBV) to enter and exit hepatocytes and to replicate. Despite this dependency, HDV can cause severe liver disease. HDV accelerates liver...